Dear colleagues and friends,

I have been asked by the council of the ERA-EDTA to briefly explain my reasons for wanting to stand for election to the ERA-EDTA council in the forthcoming June 2005 election.

As many of you know, I am a relatively young Portuguese nephrologist who trained for seven years in the USA where I did my Internal Medicine residency in New York and my fellowship in Nephrology at UCLA under the supervision of Professor Jack Coburn. I passed the American Boards and am American Board Certified in Internal Medicine and Nephrology.

I am currently a nephrologist at the university hospital and assistant professor of medicine at the medical school of Porto, where I took my doctorate. Currently, I am also the vice president of the Portuguese Society of Nephrology.

Having trained in the USA, I feel that I have much to contribute to the European Renal Association. I believe I can bring the rich experience of a medical education in the US, obviously very different to the European tradition, to the council of the association.

In addition, my intention is to become involved in the ERA-EDTA's educational activities, consolidating and extending the training efforts underway. My USA background and knowledge of research – particularly in the field of bone disease – equips me for this area. Training and education in nephrology needs to be standardised throughout European countries. This is an urgent task for the near future, and one in which I would very much like to be involved.

Prof. João M. Frazão

CURRICULUM VITAE

I. BIOGRAPHICAL

Name: João Miguel Frazão, M.D., Ph.D.

Born: Lisbon, Portugal; July 6, 1962

Nationality: Portuguese

Social Security: 104-78-5498

Home Address: Av. General Norton de Matos, 369, Bl B, Ed 2, 3ºB

                       4450 Matosinhos

                       Portugal

work Address: Hospital S. João

                      Serviço de Nefrologia

                      Al. Hernâni Monteiro

                      4200 Porto

                      Portugal

                      tel. no 351 22 5502023

II. EDUCATION

Undergraduate Training

A. High School

    Concluded in 1979 at "Liceu Nacional Gil Vicente". Lisbon, Portugal.

    Final score - 15 out of 20.

B. Pre-University year

    Concluded in 1980.

C. Admission Examination to Medical School in 1980 with the score of 15 out of 20.

D. Medical school of Lisbon 1980-86.

    Grade in Medicine concluded in 1986 with the final score of 16 out of 20.

Postgraduate Training

Rotating Internship

Two years in "Hospitais Civis de Lisboa", Lisbon.

From: January 1987.

Till: December 1988.

Residency in Nephrology

1st March 1989 till 1st November 1990 to join the mandatory Military Service (20 months).

Initiated at the Nephrology Service of "Hospitais Civis the Lisboa", Lisbon in January 1989 and interrupted till November 1990

From the 1st November 1990 till June 1991 returned to the Nephrology Service.

U.S. Postgraduate Training

Residency

Residency in Internal Medicine from July 1991 till June 1994 at St. John's Episcopal Hospital, Far Rockaway, NY. This facility is a major affiliated with Downstate Medical Center.

During the 3rd year of residency had the position of Associate Chief Resident.

Fellowship

Nephrology fellowship from July 94 till July 96 - UCLA/West Los Angeles VA Medical Center combined program.

Research Fellow

From July 1996 until July 1998, Research Fellowship, Nephrology Section, West Los Angeles VA Medical Center.

III. EXAMINATIONS AND CERTIFICATIONS

Portuguese National Examination

To obtain a position to initiate a residency/fellowship.

Date: October, 1988.

Score: 86%

Number 12 out of 1833 candidates.

Foreign Medical Graduate Examination In Medical Sciences (FMGEMS)

Examination concluded in 1990.

Basic Sciences - January 19, 1988: score 79.

Clinical Sciences - July 22, 1987: score 81.

English Examination - January 13, 1990.

Valid through - Indefinitely.

FLEX EXAMINATION

December 1992 with following scores:

Component I - 85

Component II - 86

BOARD CERTIFICATION:

Internal Medicine, American Board of Internal Medicine

Passed in August 1994 certifying examination with following scores:

- Core component - 79 percentile.

- Non-core component - 81 percentile.

Subspecialty of Nephrology, American Board of Internal Medicine

Passed in November 1996, 10th decile.

DOCTORATE/Ph.D IN MEDICINE IN THE MEDICAL SCHOOL OF PORTO, UNIVERSITYOF PORTO.

December 1999, approved with unanimously.

Thesis Title : Secondary Hyperparathyroidism in Hemodialysis Patients: From the Pathogenesis to the Treatment. A Safer Approach with a New Vitamin D Analog.

IV. APPOINTMENTS

1. Visiting Assistant Professor of Medicine, UCLA School of Medicine, Los Angeles, California (July 1996-June 1998).

2. Assistant Director of the Nephrology and the Hypertension Clinics at the West Los Angeles VA Medical Center (July 1996-June 1998).

3. Medical Consultant for Bone Care International, Inc., Madison, Wisconsin (1996-1999).

4. Full time nephrologist in the Nephrology Department, Hospital de S. João, Porto, Portugal (Since August 1998- until present).

5. Nephrologist in the outpatient Dialysis Unit: Centro Renal da Prelada, Agrupamento Médico para o Tratamento de Doenças Renais,Lda. Gambro Healthcare. (Since August 1998-until present)

6. Visiting Assistant Professor of Medicine, Medical School of Porto, University of Porto, Department of Medicine, lecturing the nephrology course (Since October 1998 - until October 2000).

7. Assistant Professor of Medicine, Medical School of Porto, University of Porto, Department of Medicine, lecturing the nephrology course (Since November 2000).

8. Medical Director in the outpatient Dialysis Unit: “Centro de Hemodiálise da Santa Casa da Misericórdia de Vila Verde”. (Since May 2002-until present)

V. MEDICAL LICENSE

California License # A055668

Portuguese License # 30323

VI. ACADEMIC OR PROFESSIONAL SOCIETIES

- International Society of Nephrology.

- "Sociedade Portuguesa de Nefrologia".

- American College of Physicians (Member).

- European Renal Association-European Dialysis and Transplant Association

VII. EDITORIAL BOARDS

Member of the editorial board of the following scientific journals:

- Nephrology Dialysis Transplantation (Since January 2000).

- Revista Portuguesa de Nefrologia e Hipertensão (Since March 1999).

VIII. PUBLICATIONS

Research Papers

Peer Reviewed

1- Oliveira C, Frazão JM, Pires C, Silva JG, Carrera F. Importância da Hemorragia Digestiva nos doentes com Insuficiência Renal Crónica em Hemodiálise. Acta Médica Portuguesa 1992;5:71-74.

2- Silva JG, Frazão JM, Oliveira C, Pires C, Carrera F. Importância do Vírus da Hepatite C como causa de Disfunção Hepática em Doentes AgHBs+. Rev Port Nefrol Hipert 1993;7:93-4.

3- Graça Silva J, Frazão JM, Oliveira C, Pires C, Carrera F. Viral Hepatitis and Hepatic Dysfunction. Analysis of a HBsAg+ Hemodialysis Population. (Abstract). Kidney Int 1993;44:1448.

4- Graça Silva J, Oliveira C, Frazão JM, Pires C, Carrera F. One year evolution of anti-HCV antibody in a Hemodialysis Population. (Abstract). Kidney Int 1993;44:1448.

5- Buff DD, Frazão JM. Atypical Presentation of Pulmonary Mucormycosis in an Elderly Alcoholic Patient With Diabetic Ketoacidosis. Rev Port Nefrol Hipert 1994;8(3):247-253.

6- Carrera F, Silva JC, Oliveira C, Frazão JM, Pires C. Persistence of Antibodies to Hepatitis C in a Chronic Hemodialysis Population. Nephron 1994;68:38-40.

7- Markowitz SR, Frazão JM. An Update in Our Understanding of a Hereditary Form of Hypertension: Glucocorticoid Suppressible Hyperaldosteronism. Rev Port Nefrol Hipert 1994;8(4):281-288.

8- Frazão JM, Barth RH, Berlyne GM. Carbamylated Hemoglobin in Pre-Renal Azotemia. Nephron 1995;71:153-155.

9- Frazão JM, Coburn JW. Symptomatic Hypercalcemia in a Diabetic Patient undergoing CAPD. Value of Bone Biopsy in the Diagnosis and Management. Am J Kidney Dis 1995;26(5):831-835.

10- Buff DD, Frazão JM, Grochowski S. Laryngeal Tuberculosis and Stridor in a Patient with AIDS. Medicina Interna 1995;2(1):26-27.

11- Coburn JW, Frazao JM. Calcitriol in the Management of Renal Osteodystrophy: A consideration of how to use calcitriol and when to treat. Seminars in Dialysis 1996;9(4):316-326.

12- Frazao JM, Coburn JW. Aluminum Toxicity in Patients with End-Stage Renal Disease: Diagnosis, Treatment and Prevention. Rev Port Nefrol Hipert 1996; 10(suppl 1): S85-S112.

13- Frazao JM, Levine BS, Tan Jr A, Mazess R, Kyllo D, Knutson J, Bishop C, Coburn JW. Efficacy and Safety of Intermittent Oral 1a(OH)-vitamin D 2 in Suppressing 2 0 hyperparathyroidism in hemodialysis patients. Dialysis & Transplantation 1997;26(9):583-595.

14- Frazao JM, Coburn JW. Safety of Magnesium Laxatives in Dialysis Patients. Seminars in Dialysis 1997;10(5):292.

15- Frazao JM, Chesney RW, Coburn JW, The 1aD 2 Study Group. Intermittent Oral 1a(OH)-vitamin D 2 is Effective and Safe for the Suppression of 2 0 Hyperparathyroidism in Hemodialysis Patients. Nephrol Dial Transplant 1998;13(Suppl 3):68-72.

16- Frazao JM, Coburn JW, Chesney RW, The 1aD 2 Study Group. Use of One-alpha-Hydroxyvitamin D 2 (1aD 2 ) in 121 Hemodialysis Patients with Secondary Hyperparathyroidism: a Phase 3 Trial. J Am Soc Nephrol 1997;8:573A (Abstract).

17- Coburn JW, Frazao JM, Chesney RW, The 1aD 2 Study Group. One-alpha-Hydroxyvitamin D 2 (1aD 2 ) Suppresses PTH in Dialysis Patients with 2 0 Hyperparathyroidism. Nephrol Dial Transplant 1997;12:1781 (Abstract).

18- Frazao JM, Elangovan L, Felsenfeld AJ, Stanley TM, Cohen AH. Epstein-Barr-virus-induced Interstitial Nephritis in an HIV-positive Patient with Progressive Renal Failure. Nephrol Dial Transplant 1998;13:1849-1852.

19- Frazao JM, Elangovan L, Levine BS. Angiotensin Converting Enzyme Inhibitors and Angiotensin Type 1 Receptor Antagonists in the Management of Progressive Chronic Renal Failure: A Comparison. Rev Port Nefrol Hipert 1998; 12:107-115.

20- Frazao JM, Coburn JW, Chesney RW, The 1aD 2 Study Group. Comparison of Intravenous with oral One-Alpha-Hydroxyvitamin D 2 (1aD 2 ) in Hemodialysis Patients with Secondary Hyperparathyroidism. J Am Soc Nephrol 1998, 9: 233A (Abstract).

21- Coburn JW, Frazao JM, Chesney RW, The 1aD 2 Study Group. Use of Intravenous One-alpha-Hydroxyvitamin D 2 (1aD 2 ) in Hemodialysis Patients with Moderate-to-Severe Secondary Hyperparathyroidism. Bone 1998, 23 (Suppl 5): S456 (Abstract).

22- Frazao JM, Coburn JW, Chesney RW, The 1aD 2 Study Group. Serum Osteocalcin and Bone Alkaline Phosphatase in Hemodialysis Patients with Secondary Hyperparathyroidism Treated with One- alpha-Hydroxyvitamin D 2 : Evidence for Direct Action on Bone. Bone 1998, 23 (Suppl. 5): S457 (Abstract).

23- Coburn JW, Elangovan L, Goodman WG, Frazão JM. The Calcium Sensing Receptor and Calcimimetic Agents. Kidney Int: 1999, 56(Suppl. 73): S52- S58.

24- Coburn JW, Elangovan L, Frazão JM, Chesney RW, The 1 a D 2 Study Group. Factors Predicting Hypercalcemia During Treatment with 1 a -Hydroxyvitamin D 2 : Role of Pre-Treatment Serum Calcium and Bone Turnover. J Am Soc Nephrol 1999, 10: 607A (Abstract).

25- Goodman WG, Frazao JM, Goodkin DA, Turner S, Liu W, Coburn JW. The Calcimimetic, R568, Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism. Kidney Int 2000, 58:436-445.

26- Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kylo DM, Douglass LL, Bishop CW, Coburn JW. Intermittent Doxercalciferol (1- a -Hydroxyvitamin D 2 ) Therapy for Secondary Hyperparathyroidism: Results of a Multicenter, Double Blinded, Controlled Study. Am J Kidney Dis 2000, 36: 550-561.

27- Maung HM, Elangovan L, Frazão JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Goodman WG, Chesney RW, Mazess RB, Kylo DM, Douglass LL, Bishop CW, Coburn JW. The Efficacy and Side-Effects of Intermittent Intravenous and oral Doxercalciferol (1 µ -hydroxyvitamin D 2 ) in Dialysis Patients with Secondary Hyperparathyroidism: A Sequential Comparison. Am J Kidney Dis 2001,37: 532-543.

28- Frazão JM, Nagami GT, Levine BS. The Transtubular Potassium Gradient in Subjects with Varying Degrees of Chronic Renal Failure.

29- Frazão JM, Nagami GT, Levine BS. The Exchangeable Sodium Ratio in Patients with Chronic Renal Disease. J Am Soc Nephrol 2001,12:135A (Abstract).

30- Frazão JM, Martins P, Coburn JW. The calcimimetic agents: perspectives for treatment. Kidney Int 2002, 61 (Suppl.80):S149-S154

31 – Goodman WG, Fadda GZ, Finkelstein FO, Mittman N, Lien YH, Leblanc M, Locatelli F, Frazão JM, Olgaard K, Olson KA, McCary LC, Turner SA Quarles LD. Calcimimetic, cinacalcet HCL as an effective primary therapy in the management of secondary hyperparathyroidism (HPT). Am Soc Nephrol 14: 460A, 2003.

32 – Ureña P, Frazão JM. Calcimimetics agents: Review and perspectives. Kidney Int 2003, 63 (Suppl.85):S91-S96.

33 - Frazão JM, Nicolini M, Torregrossa V, Kerr P, Jaeger P, Sprague SM, Jadoul M, Mellotte G, Neyer U, Geiger H, Hagen EC, McCary L, Baker N, Turner S, Quarles LD. Cinacalcet HCL effectively reduces intact parathyroid hormone (iPTH) and CaXP irrespective of the severity of secondary hyperparathyroidism (HPT). ERA-EDTA XLI Congress Abstract Book: 219, 2004.

34 – Malluche HH, Monier-Faugere MC, Wang G, Frazão JM, Charytan C, Coburn J, Coyne D, Kaplan M, Baker N, McCary LC, Turner SA, Goodman WG. Cinacalcet HCL reduces bone turnover and area of fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). ERA-EDTA XLI Congress Abstract Book: 218, 2004.

35 – Frazão JM, Martins P, Santos-Araújo C. O receptor de cálcio e a experiência clínica com o agente calcimimético – Cinacalcet HCL. Rev Port Nefrol Hipert 2004; 18 (Supl 1): 31-41.

Book Chapters

1- Frazão JM, Coburn JW. Aluminum Toxicity. In: Llach F, Valderrábano F, eds. Insuficiencia Renal Crónica, Diálisis y Trasplante Renal, 2nd Edition. Madrid, Ediciones Norma, 1997: 375-402.

2- Tan, Jr A, Frazao JM, Nemeh M, Nikakhtar B, Levine BS. Divalent Ion Metabolism.

In: Gonick HC, ed. Current Nephrology, 20th edition. St. Louis, Mosby , 1997: 101-133.

3- Coburn JW, Frazao JM. Thromboembolism to the Kidney and Atheroembolic Disease. In: Bone RC. Current Practice of Medicine, 2 nd edition. Editor Nephrology, Richard J. Glassock, Section Editor. Philadelphia, Current Science, 1999: 1541-1545.

4- Frazao JM, Coburn JW. Aluminum Toxicity. In Massry SG, Glassock RJ, eds. Textbook of Nephrology, 4th Edition. Baltimore, Williams & Wilkins, 2001: 1244-1258.

5- Coburn JW, Maung HM, Frazao JM, Elangovan L. New Vitamin D Analogs and Calcimimetics. In Drüeke T, Salusky I, eds. The Spectrum of Renal Osteodystrophy, 1th Edition. Oxford University Press, 2001: 513-531.

6– Coburn JW, Frazão JM. Management of Aluminum Toxicity. In Nissenson AR, Fine RN, eds. Dialysis Therapy, 3 rd Edition. Philadelphia, Hanley & Belfus, Inc, 2002: 405-409.

7 – Frazão JM, Carrera F. Doença Glomerular, Síndrome Nefrítica e Síndrome Nefrótica. In Ponce P, ed. Manual de Terapêutica Médica, 1ª Edição. Lidel, 2002: 40-50.

8- Coburn JW, Frazão JM. Vitamin D Normal Physiology and Vitamin D Therapeutics in Normal Nutrition and Various Diseas e States. In Morii H, Nishizawa Y, Massry SG, eds. Calcium in Internal Medicine, 1 st Edition. Springer-Verlag London, 2002: 261-305.

9- Carrera F, Frazão JM. Thromboembolism and Atheroembolic Disease of the Kidney. In: Schena FP, ed. Textbook of Nephrology, 1st Edition. Mcgraw-Series of Clinical Medicine, 2001: 355-359.

João M. Frazão, M.D. PhD

May 2005